Alnylam Pharmaceuticals
ALNY
#649
Rank
A$56.93 B
Marketcap
A$426.42
Share price
2.04%
Change (1 day)
-14.41%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): A$5.61

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is A$5.50. In 2025 the company made an earnings per share (EPS) of A$2.61.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$5.61114.84%
2025A$2.61
2023A-$5.12-62%
2022A-$13.4729.03%
2021A-$10.44-3.36%
2020A-$10.80-8.48%
2019A-$11.807.67%
2018A-$10.9639.74%
2017A-$7.8512.94%
2016A-$6.9538.84%
2015A-$5.00-32.88%
2014A-$7.45259.44%
2013A-$2.07-31.25%
2012A-$3.02

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
A$10.18 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$3.71-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$61.67 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A-$12.06-319.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A-$1.06-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A-$0.35-106.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$1.99-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A$0.51-90.77%๐Ÿ‡บ๐Ÿ‡ธ USA